DigestRedComo funciona
Red
/
Empresas
Mo
No verificado

Modalis Therapeutics Corporation

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaIr de comprasSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
10/09/2026
Multimedia
Mercado laboral
Salud
Biotecnología
Ciencia
Farmacéutica
Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy
Fuente
Modalis Therapeutics Corporation
Editor
Business Wire
1.00
0
25/12/2025
Salud
Ir de compras
Biotecnología
Asistencia a la infancia
Farmacéutica
Industria
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
Fuente
Modalis Therapeutics Corporation
Editor
Business Wire
1.00
0
12/05/2025
Eventos
Licitaciones y contratas
Ciencia
Jóvenes
Biotecnología
Medicina - Varios
Farmacéutica
Ir de compras
Salud
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
Fuente
Modalis Therapeutics Corporation
Editor
Business Wire
1.00
0
06/01/2025
Multimedia
Mercado laboral
Industria
Biotecnología
Salud
Farmacéutica
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
Fuente
Modalis Therapeutics Corporation
Editor
Business Wire
1.00
0
25/10/2024
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
Fuente
Modalis Therapeutics Corporation
Editor
Business Wire
1.00
0
30/09/2024
Industria
Salud
Higiene alimentaria
Ir de compras
Biotecnología
Infancia
Farmacéutica
Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
Fuente
Modalis Therapeutics Corporation
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0